COX-2 inhibitor protection against skin cancer questionable

被引：0
|
作者：
Klein, Friederike
机构：
来源：
AKTUELLE DERMATOLOGIE | 2023年 / 49卷 / 06期
关键词：
D O I：
10.1055/a-2054-7374
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [1] COX-2 inhibitor
    Gotzsche, P. C.
    Bjarnasoni, N. H.
    RHEUMATOLOGY, 2007, 46 (10) : 1623 - 1624
  • [2] COX-2 inhibitor use and risk of skin cancer: three prospective cohort studies
    Yen, Hsuan
    Yen, Hsi
    Drucker, Aaron
    Han, Jiali
    Li, Wen-Qing
    Li, Tricia
    Qureshi, Abrar
    Cho, Eunyoung
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Celecoxib: A COX-2 inhibitor
    Andrews, SA
    Wallace, CK
    Davis, RL
    AMERICAN JOURNAL OF MANAGED CARE, 1999, 5 (04): : 511 - 518
  • [4] COX-2 immunoexpression in inflammatory breast cancer. A rationale base for a neoadjuvant treatment with COX-2 inhibitor
    Manfrin, Erminia
    Remo, Andrea
    Martignoni, Guido
    Brunelli, Matteo
    Reghellin, Daniela
    Dal Fior, Daniela
    Franceschetti, Ilaria
    Rapagnani, Maria Paola
    Parisi, Alice
    Menestrina, Fabio
    Bonetti, Franco
    MODERN PATHOLOGY, 2006, 19 : 16 - 16
  • [5] Cox-2 inhibitor improves radiation treatment in lung cancer
    Grimes, KR
    Warren, GW
    St Clair, WH
    FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 : S133 - S134
  • [6] Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer
    Rao, P. N. Praveen
    Grover, Rajesh K.
    IDRUGS, 2009, 12 (11) : 711 - 722
  • [7] COX-2 Inhibitor, Celecoxib, May Prevent Lung Cancer
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (09): : 848 - 849
  • [8] Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor
    Eibl, G
    Takata, Y
    Boros, LG
    Liu, J
    Okada, Y
    Reber, HA
    Hines, OJ
    CANCER RESEARCH, 2005, 65 (03) : 982 - 990
  • [9] Cox-2 linked to heart protection
    Dalton, L
    CHEMICAL & ENGINEERING NEWS, 2004, 82 (47) : 15 - 15
  • [10] COX-2 alternatives and GI protection
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2004, 46 (1195): : 91 - 92
12345